Navigation Links
XBiotech to Present at UBS Global Healthcare Conference
Date:5/1/2013

AUSTIN, Texas, May 1, 2013 /PRNewswire/ -- XBiotech announced today that John Simard , Chairman, President & Chief Executive Officer, will present at the UBS Global Healthcare Conference in New York, NY on Monday, May 20th at 1:30pm ET.  The conference will take place at the Sheraton New York Hotel May 20-22, 2013.

John Simard remarked "XBiotech is delighted to be invited by UBS to present at this prestigious venue. UBS is one of the greatest financial institutions in the world and we are indeed honored to be asked to share our story at their conference."

About True Human™ Antibodies
True Human antibodies represent the next generation of therapeutic antibodies. True Human antibodies are "invisible" to the body's immune system and thus have the potential for better safety, efficacy and patient tolerability compared to earlier generation antibody therapeutics.

About XBiotech
XBiotech is pioneering breakthrough therapies that improve the safety and efficacy of antibody therapeutics. The Company's lead product candidate inhibits chronic sterile inflammation by targeting IL-1a, a master regulator of inflammation. The clinical development program addresses tremendous unmet medical need in multiple disease indications including, acne, psoriasis, cachexia, cancer, type 2 diabetes and cardiovascular disease. XBiotech is also revolutionizing scalable, flexible manufacturing systems for the production of biological therapies.  Using minimal infrastructure and disposable bioreactor technology – to dramatically reduce capital requirements, operating complexity, and lead times - the Company has established a compelling commercialization path for its True Human antibody platform.  XBiotech is building on a foundation of groundbreaking therapies, innovation and a commitment to unmet medical needs worldwide. For more information on how XBiotech is advancing human monoclonal antibody therapy please visit www.xbiotech.com.

Contact: 
Investors: 
Erika Geimonen, Ph.D.
XBiotech
info@xbiotech.com
512.386.2906                                                        


'/>"/>
SOURCE XBiotech
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. XBiotech Reports Positive Phase II Interim Analysis Results in Vascular Disease
2. XBiotech Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study
3. Leonhardt Ventures to Present Technology Showcase @ Heart Rhythm 2013
4. Vatsala Naageshwaran of Absorption Systems to Present at Disso 2013 International Conference in Mumbai, India on May 3rd
5. Organogenesis to Present Large Retrospective Comparative Effectiveness Analysis and Health Economic Data in Chronic Wound Healing at The Symposium on Advanced Wound Care and Wound Healing Society Meeting
6. Cardium Announces Excellagen Presentation at the Symposium on Advanced Wound Care Spring 2013 Meeting
7. Epilepsy Foundation To Present Epilepsy Therapy Project Lifetime Accelerator Award To Henrik Klitgaard, Ph.D., Recognizing Contributions To New Therapies
8. Neuralstem ALS Trial Data Presented At The American Association Of Neurological Surgeons Annual Meeting
9. Anterios, Inc. CEO And Founder, Jon Edelson, To Present At Needham & Companys 12th Annual Healthcare Conference
10. Rush University Medical Center Presents Positive MuGard Clinical Data at the Oncology Nursing Society 38th Annual Congress
11. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... AROMAS, Calif. , Aug. 2, 2017 /PRNewswire/ ... by Continental Who,s Who as a Pinnacle Lifetime ... currently the Key Account Manager at Turing Pharmaceuticals, ... communications, negotiations, troubleshooting and relationship building.                ... has more than 25 years of experience ...
(Date:7/31/2017)... FLINT, Mich. , July 31, 2017  Diplomat Pharmacy, ... companies in southeast Michigan by ... feature ranks private and public companies by three-year revenue growth. ... To view the complete list, ... Crain,s Fast 50 is an incredible triumph," said Phil ...
(Date:7/27/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported ... The Company reported second quarter net sales of $1.954 ... period, and an increase of 2.1% on a constant ... from the LDR Holding Corporation acquisition, second quarter 2017 ... or 0.3% on a constant currency basis. ...
Breaking Medicine Technology:
(Date:8/17/2017)... , ... August 17, 2017 , ... Inc. Magazine Unveils ... at No. 132 with Three-Year Sales Growth of 3,004.8% , NEW YORK, August 16, ... Inc. 5000, the most prestigious ranking of the nation's fastest-growing private companies. The list ...
(Date:8/17/2017)... , ... August 17, 2017 , ... ... Employers , an international competition, were announced today. The awards recognize the world’s ... suppliers who help to create and drive great places to work. , A ...
(Date:8/16/2017)... ... August 16, 2017 , ... Blue Health Intelligence (BHI) ... President, Chief Medical Officer. Dr. Spiro brings over 30 years of clinical, healthcare IT, ... for BHI’s cutting-edge analytics solutions. , “I am thrilled to welcome Dr. Spiro ...
(Date:8/16/2017)... Atlanta, GA (PRWEB) , ... August 16, 2017 , ... ... the new Inc. 5000. The company ranked #4429 on the newly released, 36th annual ... The list represents a unique look at the most successful companies within the American ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... their recently launched community enrichment program. Partnering once again with Boys & Girls ... competition to help find the area’s very own American Idol. With all proceeds ...
Breaking Medicine News(10 mins):